Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.119836 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Clotilde Guidetti und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Child Neuropsychiatry Unit, Department of Neurosci…. Hauptthemen laut MEDLINE: Antidepressive Agents, Aripiprazole, Cognition, Major Depressive Disorder. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Patient-Centered Outcomes Research Institute.
Themen: Depression
Abstract (Originalsprache)
Subjective cognitive impairment is a key symptom of major depressive disorder (MDD). Improvement of cognitive function in patients with treatment-resistant depression (TRD) is an important treatment outcome. This study compared the impact of augmenting antidepressants with aripiprazole or repetitive transcranial magnetic stimulation (rTMS) versus switching to venlafaxine (or duloxetine for those not eligible to receive venlafaxine) on cognition in TRD patients. In a pre-defined secondary analysis of a multi-site, open-label trial, patients with TRD were randomly assigned to aripiprazole augmentation, rTMS augmentation, or switching to venlafaxine XR/duloxetine in 1:1:1 ratio and they were treated for 8 weeks. Cognition was assessed using the Cognitive and Physical Functioning Questionnaire (CPFQ). A mixed-effects model with repeated measures was conducted. Among the 258 randomized subjects with at least one post-baseline CPFQ assessment (aripiprazole n = 91; rTMS = 70;venlfaxine XR/duloxetine = 97), neither aripiprazole nor rTMS demonstrated significant differences compared to the venlafaxine XR/duloxetine switch group in cognitive outcome as measured by CPFQ scale (p > 0.025). The mean (SE) change in CPFQ scores from baseline to Week 8 was -8.04 (0.77) (aripiprazole augmentation) versus -6.70 (0.75) (venlafaxine XR/duloxetine switch), and - 8.81 (0.64) (rTMS augmentation) versus -6.72 (0.55) (venlafaxine XR/duloxetine switch). Hedge's g values were 0.21 for aripiprazole augmentation versus switching to venlafaxine XR/duloxetine and 0.33 for rTMS augmentation versus switching to venlafaxine XR/duloxetine. Although rTMS augmentation did not reach a statistically significant difference in subjective cognitive improvement, it showed a larger effect size compared to aripiprazole augmentation. Our findings signal that rTMS augmentation may offer a well-tolerated strategy for improving cognition in TRD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Child Neuropsychiatry Unit, Department of Neuroscience, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy. Electronic a…
- Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- University of Texas Southwestern Medical Center, Dallas, TX, United States of America.
- University of Alabama at Birmingham, Birmingham, AL, United States of America.
- Nathan Kline Institute for Psychiatric Research and New York University School of Medicine, New York, NY, United States of America.
- Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, United States of America.
Förderung
- Patient-Centered Outcomes Research Institute
Zitieren
APA
Guidetti, C., Chaikali, S., Trivedi, M. H., Shelton, R. C., Iosifescu, D. V., Thase, M. E., Jha, M. K., Mathew, S. J., DeBattista, C., Dokucu, M. E., Brawman-Mintzer, O., Ortiz, J. M. H., Currier, G. W., McCall, W. V., Modirrousta, M., Macaluso, M., Bystritsky, A., Vila-Rodriguez, F., Nelson, E. B., …, & Papakostas, G. I. (2025). Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119836
Vancouver
Guidetti C, Chaikali S, Trivedi MH, Shelton RC, Iosifescu DV, Thase ME, et al. Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD). Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119836
BibTeX
@article{Guidetti2025,
author = {Guidetti, Clotilde and Chaikali, Stefania and Trivedi, Madhukar H and Shelton, Richard C and Iosifescu, Dan V and Thase, Michael E and Jha, Manish K and Mathew, Sanjay J and DeBattista, Charles and Dokucu, Mehmet E and Brawman-Mintzer, Olga and Ortiz, Jesús Manuel Hernández and Currier, Glenn W and McCall, William Vaughn and Modirrousta, Mandana and Macaluso, Matthew and Bystritsky, Alexander and Vila-Rodriguez, Fidel and Nelson, Erik B and Yeung, Albert S and MacGregor, Leslie C and Carmody, Thomas and Fava, Maurizio and Papakostas, George I},
title = {Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD)},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.119836}
}
EUVIMED